We are delighted to announce that 6 new projects have been selected by the Pôle Cancer Paris Saclay (PSCC) to benefit from its support: Acobiom, Genexpath, Letsee Imaging, EnnoDC (formerly LinKinVax), Quintessence, and Raidium
Each of these innovative projects is driving breakthroughs in diagnostics, medical devices and biotechnology, helping to advance cancer treatment and patient care.
- ACOBIOM specializes in diagnostics, developing the GEMCITEST® to predict patients' responses to gemcitabine treatment for cancer.
- Genexpath creates and markets tests that better characterize cancers such as non-Hodgkin’s lymphoma and sarcomas.
- Letsee Imaging is revolutionizing mammography with a disruptive technology that detects small masses in dense breast tissue, enabling early cancer diagnosis.
- EnnoDC (formerly LinKinVax) is in clinical development, targeting dendritic cells to improve treatment outcomes for oropharyngeal cancer.
- Quintessence is focused on innovative approaches to boost cell therapy production efficiency and purity.
- Raidium enhances radiological analysis using AI to improve tumor detection and track tumor evolution.
With 50 cutting-edge oncology projects selected and supported, the #PSCC offers the most promising developers access to a comprehensive set of resources to accelerate innovation in oncology: expertise, networking, funding, data, samples, technologies, infrastructure, training, laboratories.
Are you developing an innovative solution for oncology patients? Join us: https://lnkd.in/eTYvAZV7
Comentarios